Clinical Trial Update: Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial assessing the safety and efficacy of rAAV.sFlt-1 gene therapy in patients with exudative age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• rAAV.sFlt-1 (recombinant adeno-associated virus expressing soluble fms-like tyrosine kinase-1)

Snippet

Sponsor: Lions Eye Institute, Perth, Western Australia | Conditions: Macular Degeneration, Age-related Maculopathies | Phase 1, Phase 2 | Status: COMPLETED